Breast Lobular Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BRS113 MIFTS: 55	Breast Lobular Carcinoma Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Breast Lobular Carcinoma

MalaCards integrated aliases for Breast Lobular Carcinoma:

Name: Breast Lobular Carcinoma ¹¹ ²⁸ ⁵ ¹⁴

Lobular Breast Carcinoma ¹⁶

Cancer, Breast, Lobular ³⁸

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0050938

EFO ¹⁶ EFO_0008509

Sources

Summaries for Breast Lobular Carcinoma

Disease Ontology: ¹¹ A breast carcinoma that derives from breast lobules (milk glands).

MalaCards based summary: Breast Lobular Carcinoma, also known as lobular breast carcinoma, is related to cervical adenocarcinoma and linitis plastica. An important gene associated with Breast Lobular Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Oxybutynin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone marrow, and related phenotypes are Decreased viability in pancreas lineage and Increased cell death in HCT116 cells

Sources

Related Diseases for Breast Lobular Carcinoma

Diseases related to Breast Lobular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 577)

#	Related Disease	Score	Top Affiliating Genes
1	cervical adenocarcinoma	30.7	TP53 PGR KRT7 ESR1
2	linitis plastica	30.7	PIP PGR KRT7 GATA3 ERBB2 CDH1
3	papillary carcinoma	30.6	MUC1 KRT7 ESR1 ERBB2 CDH1
4	gastric adenocarcinoma	30.5	TP53 PTEN PIK3CA ERBB2 CDH1
5	fasciitis	30.5	TP53 MUC1 ESR1
6	leiomyoma, uterine	30.5	PGR ESR1 CYP19A1
7	inherited cancer-predisposing syndrome	30.4	TP53 PTEN EGFR CDH1 BRCA2 BRCA1
8	bap1 tumor predisposition syndrome	30.4	TP53 PTEN EGFR CDH1 BRCA2 BRCA1
9	gastroesophageal reflux	30.3	TP53 GATA3 EGFR EGF
10	anus cancer	30.3	TP53 PIK3CA KRT7 ERBB2 EGFR
11	leiomyoma	30.3	TP53 PGR ESR1 EGF CYP19A1
12	breast metaplastic carcinoma	30.3	TP53 PGR KRT7 KRT5 ESR1 ERBB2
13	breast disease	30.3	TP53 PGR ESR1 ERBB2 EGF CYP19A1
14	diffuse gastric cancer	30.2	TP53 PTEN PIK3CA ERBB2 CTNND1 CDH1
15	diffuse gastric and lobular breast cancer syndrome	30.2	TP53 PTEN PIK3CA ERBB2 CTNND1 CDH1
16	gastric diffuse adenocarcinoma	30.2	PIP PGR KRT7 GATA3 ESR1 ERBB2
17	endometrial adenocarcinoma	30.2	TP53 PTEN PGR KRT7 ESR1 EGFR
18	skin carcinoma	30.1	TP53 PTEN KRT7 KRT5 ERBB2 EGFR
19	mammary paget's disease	30.1	PIP PGR MUC1 KRT7 ESR1 ERBB2
20	colon adenocarcinoma	30.1	TP53 PIK3CA ESR1 EGFR EGF CTNND1
21	spinal cord disease	30.0	TP53 PTEN EGFR
22	bilateral breast cancer	29.9	TP53 PTEN PGR ESR1 ERBB2 CYP19A1
23	breast fibroadenoma	29.9	TP53 PGR KRT5 ESR1 ERBB2 EGFR
24	sweat gland cancer	29.9	TP53 PIP PGR KRT7 KRT5 GATA3
25	colonic benign neoplasm	29.8	TP53 PTEN PIK3CA KRT7 ESR1 ERBB2
26	squamous cell carcinoma	29.8	TP53 PTEN PIK3CA MUC1 KRT7 ERBB2
27	meningioma, familial	29.7	TP53 PTEN PIK3CA PGR MUC1 ESR1
28	gastric cancer	29.7	TP53 PTEN PIK3CA MUC1 ESR1 ERBB2
29	lobular neoplasia	29.7	TP53 PTEN PIP PIK3CA PGR KRT5
30	adenocarcinoma	29.7	TP53 PTEN PIK3CA MUC1 KRT7 ERBB2
31	apocrine adenocarcinoma	29.6	TP53 PIP PIK3CA PGR KRT7 KRT5
32	leukemia, acute myeloid	29.6	TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
33	bladder cancer	29.6	TP53 PTEN PIK3CA MUC1 KRT7 ESR1
34	renal cell carcinoma, nonpapillary	29.6	TP53 PTEN PIK3CA MUC1 KRT7 ESR1
35	ovarian cancer	29.5	TP53 PTEN PIK3CA PGR MUC1 KRT7
36	breast carcinoma in situ	29.4	TP53 PTEN PIP PIK3CA PGR MUC1
37	lung cancer	29.3	TP53 PTEN PIK3CA MUC1 KRT7 ESR1
38	breast ductal carcinoma	29.1	TP53 PTEN PIP PGR MUC1 KRT7
39	breast cancer	29.1	TP53 PTEN PIP PIK3CA PGR MUC1
40	ductal carcinoma in situ	29.1	TP53 PTEN PIP PIK3CA PGR MUC1
41	colorectal cancer	29.0	TP53 PTEN PIK3CA PGR MUC1 KRT7
42	endometrial cancer	28.9	TP53 PTEN PIK3CA PGR MUC1 KRT7
43	breast adenocarcinoma	28.9	TP53 PTEN PIP PIK3CA PGR MUC1
44	uterine corpus adenosarcoma	10.5	PGR ESR1
45	adult cystic nephroma	10.5	PGR ESR1
46	her2-receptor negative breast cancer	10.5	PGR ERBB2
47	vagina leiomyosarcoma	10.5	PGR ESR1
48	euryblepharon	10.5	CTNND1 CDH1
49	vulvar benign neoplasm	10.5	PGR ESR1
50	mucoepidermoid esophageal carcinoma	10.5	TP53 KRT5

Graphical network of the top 20 diseases related to Breast Lobular Carcinoma:

Sources

Symptoms & Phenotypes for Breast Lobular Carcinoma

GenomeRNAi Phenotypes related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.18	AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
2	no effect	GR00402-S-2	10.18	AR BRCA1 BRCA2 CTNND1 CYP19A1 EGF
3	Decreased viability in pancreas lineage	GR00235-A	9.13	KRT7 PGR TP53
4	Increased cell death in HCT116 cells	GR00103-A-0	8.85	PIK3CA

MGI Mouse Phenotypes related to Breast Lobular Carcinoma:

⁴⁵ (show all 22)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.45	AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
2	neoplasm	MP:0002006	10.44	AR BRCA1 BRCA2 CDH1 CTNND1 EGFR
3	normal	MP:0002873	10.44	AR BRCA1 BRCA2 CDH1 CYP19A1 EGF
4	homeostasis/metabolism	MP:0005376	10.43	AR BRCA1 BRCA2 CDH1 CYP19A1 EGFR
5	growth/size/body region	MP:0005378	10.41	AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
6	digestive/alimentary	MP:0005381	10.41	AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
7	nervous system	MP:0003631	10.35	AR BRCA1 BRCA2 CTNND1 CYP19A1 EGFR
8	cellular	MP:0005384	10.34	AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
9	muscle	MP:0005369	10.3	AR BRCA1 CYP19A1 EGFR ERBB2 ESR1
10	renal/urinary system	MP:0005367	10.27	AR BRCA1 CTNND1 CYP19A1 EGFR ESR1
11	immune system	MP:0005387	10.27	AR BRCA1 BRCA2 CDH1 CYP19A1 EGF
12	embryo	MP:0005380	10.26	AR BRCA1 BRCA2 CDH1 EGFR ERBB2
13	limbs/digits/tail	MP:0005371	10.25	AR BRCA1 BRCA2 EGFR ERBB2 ESR1
14	cardiovascular system	MP:0005385	10.22	AR BRCA1 CDH1 CYP19A1 EGFR ERBB2
15	reproductive system	MP:0005389	10.2	AR BRCA1 BRCA2 CDH1 CYP19A1 EGF
16	no phenotypic analysis	MP:0003012	10.19	CDH1 EGFR ESR1 GATA3 MUC1 PGR
17	adipose tissue	MP:0005375	10.19	AR BRCA1 CYP19A1 EGFR ESR1 GATA3
18	pigmentation	MP:0001186	10.15	AR BRCA1 CYP19A1 EGFR GATA3 PTEN
19	skeleton	MP:0005390	10.03	AR BRCA1 BRCA2 CYP19A1 EGFR ERBB2
20	hematopoietic system	MP:0005397	9.93	AR BRCA1 BRCA2 CYP19A1 EGFR ERBB2
21	mortality/aging	MP:0010768	9.83	AR BRCA1 BRCA2 CDH1 CTNND1 EGFR
22	integument	MP:0010771	9.58	AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1

Sources

Drugs & Therapeutics for Breast Lobular Carcinoma

Drugs for Breast Lobular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Oxybutynin

Approved, Investigational

Phase 3

5633-20-5

4634

Metformin

Approved

Phase 3

1115-70-4, 657-24-9

4091

Anastrozole

Approved, Investigational

Phase 3

120511-73-1

2187

Fulvestrant

Approved, Investigational

Phase 3

129453-61-8

17756771 104741

Neurotransmitter Agents

Phase 3

Parasympatholytics

Phase 3

Mandelic Acids

Phase 3

Anti-Infective Agents

Phase 3

Muscarinic Antagonists

Phase 3

Cholinergic Antagonists

Phase 3

Cholinergic Agents

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Estrogens

Phase 3

Estrogen Receptor Antagonists

Phase 3

Estrogen Antagonists

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Hypoglycemic Agents

Phase 3

Aromatase Inhibitors

Phase 3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Epirubicin

Approved

Phase 2

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Vinorelbine

Approved, Investigational

Phase 2

71486-22-1

44424639 60780

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Entrectinib

Approved, Investigational

Phase 2

1108743-60-7

25141092

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Goserelin

Approved

Phase 2

65807-02-5

5311128 47725

Crizotinib

Approved, Investigational

Phase 2

877399-52-5

11626560

Antimetabolites

Phase 2

Antirheumatic Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Alkylating Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Antimitotic Agents

Phase 2

Angiogenesis Inhibitors

Phase 2

Tubulin Modulators

Phase 2

Antibiotics, Antitubercular

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Omega 3 Fatty Acid

Phase 2

Protein Kinase Inhibitors

Phase 2

Pharmaceutical Solutions

Phase 2

Atorvastatin

Approved

Phase 1

134523-00-5

60823

Carbamide peroxide

Approved

Phase 1

124-43-6

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 1

62-33-9, 60-00-4

6049

Pentetic acid

Approved

Phase 1

67-43-6

Tamoxifen

Approved

Phase 1

10540-29-1, 54965-24-1

2733526

Interventional clinical trials:

(show all 39)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes	Completed	NCT02961790	Phase 3	Oxybutynin Chloride
2	Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women	Active, not recruiting	NCT01905046	Phase 3	metformin hydrochloride
3	Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study	Active, not recruiting	NCT01953588	Phase 3	fulvestrant;anastrozole
4	RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction	Active, not recruiting	NCT03414970	Phase 3
5	"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"	Unknown status	NCT01641406	Phase 2	Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
6	Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy	Unknown status	NCT02314156	Phase 2	Telapristone Acetate
7	A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease	Completed	NCT01849250	Phase 2	Docosahexaenoic Acid
8	A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma	Completed	NCT01869764	Phase 2	omega-3 fatty acid
9	Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)	Recruiting	NCT03979508	Phase 2	Abemaciclib
10	Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast	Recruiting	NCT04551495	Phase 2	Entrectinib;Letrozole;Goserelin
11	[18F]Fluoroestradiol-Positron Emission Tomography (PET)/CT Imaging of Invasive Lobular Carcinoma	Recruiting	NCT04252859	Phase 2	[18F]Fluoroestradiol (FES) PET/CT
12	Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours	Recruiting	NCT03620643	Phase 2	Crizotinib Oral Capsule [Xalkori];Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
13	Accelerated, Hypofractionated Post-Mastectomy Radiation Therapy in Women With Breast Cancer: A Phase II Trial	Active, not recruiting	NCT01417286	Phase 2
14	Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer	Terminated	NCT01754519	Phase 2
15	A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer	Withdrawn	NCT01100489	Phase 2
16	A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer	Completed	NCT00637481	Phase 1	atorvastatin calcium
17	Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer	Completed	NCT01077453	Phase 1	letrozole
18	Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging	Recruiting	NCT04750473	Phase 1	Fluciclovine F18;Gallium Ga 68 Gozetotide
19	Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery	Active, not recruiting	NCT03317405	Phase 1	Endoxifen Hydrochloride
20	A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer	Active, not recruiting	NCT03323658	Phase 1	Bexarotene
21	Monitoring Response After The First Chemotherapy Cycle In Newly Diagnosed Breast Cancer As A Guide For Neoadjuvant Therapy	Unknown status	NCT01038258
22	A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients	Completed	NCT01819233
23	Diet, Exercise and Estrogen Metabolites Study (DEEM)	Completed	NCT01874184
24	Living Well After Breast Surgery	Completed	NCT03834532
25	Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial	Completed	NCT01975363
26	Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial	Completed	NCT01688388
27	A Pilot Study of Broccoli Sprout Extract in Patients With Breast Cancer	Completed	NCT01753908	Early Phase 1	Broccoli Sprout Extract
28	Psychoeducation for Spouses/Partners of Women With Breast Cancer	Completed	NCT01723943
29	Choosing Neoadjuvant Chemotherapy Versus Hormonal Therapy for Breast Cancer Based on Gene Expression Profile	Completed	NCT01293032		Systemic Chemotherapy;Tamoxifen Citrate;Aromatase Inhibition Therapy
30	Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer	Recruiting	NCT05086705
31	Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)	Recruiting	NCT04496739
32	Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women With Breast Cancer - HeNRIetta	Recruiting	NCT02515110
33	LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients	Recruiting	NCT05410951
34	Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)	Active, not recruiting	NCT01706432
35	Understanding How CDH1 Germline Mutations Affect Hereditary Lobular Breast Cancer	Active, not recruiting	NCT04206891
36	Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer	Active, not recruiting	NCT04021069
37	Soy Treatment for High-risk Women	Active, not recruiting	NCT01219075
38	Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute	Not yet recruiting	NCT05178498
39	Intraoperative Stereotactic Image-guided Navigation of Perforators for DIEP Flap Breast Reconstruction.	Withdrawn	NCT01729832

Search NIH Clinical Center for Breast Lobular Carcinoma

Sources

Genetic Tests for Breast Lobular Carcinoma

Genetic tests related to Breast Lobular Carcinoma:

#	Genetic test	Affiliating Genes
1	Breast Lobular Carcinoma ²⁸

Sources

Anatomical Context for Breast Lobular Carcinoma

Organs/tissues related to Breast Lobular Carcinoma:

MalaCards : Breast, Lymph Node, Bone Marrow, Colon, Skeletal Muscle, Bone, Thyroid

Sources

Publications for Breast Lobular Carcinoma

Articles related to Breast Lobular Carcinoma:

(show top 50) (show all 405)

#	Title	Authors	PMID	Year
1	Germline E-cadherin mutations in familial lobular breast cancer. ⁵	Masciari S...Huntsman D	17660459	2007
2	E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. ⁵	Berx G...van Roy F	8557030	1995
3	De novo metastatic lobular breast carcinoma: A population-based study from SEER database. ⁶²	Sun MS...Xu L	35012851	2022
4	Genomic assays for lobular breast carcinoma. ⁶²	Goker M...Braems G	36451999	2022
5	Plexiform tumorlet in a woman with postmenopausal endometrioid endometrial carcinoma taking tamoxifen for breast cancer: A case report. ⁶²	Koufopoulos N...Dimitrakakis C	36389630	2022
6	Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. ⁶²	Elangovan A...Lee AV	35665642	2022
7	Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas. ⁶²	Lee S...Osmanbeyoglu HU	35906698	2022
8	Efficacy of breast magnetic resonance for surgical decision in mixed invasive ductal and lobular breast carcinoma. ⁶²	Kang B...Jeong JY	35382971	2022
9	Metastatic Neoplasms Involving the Stomach. ⁶²	Vyas M...Jessurun J	34875001	2022
10	Development of Histologically Verified Thyroid Diseases in Women Operated for Breast Cancer: A Review of the Literature and a Case Series. ⁶²	Fama' F...Dionigi G	35683541	2022
11	Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. ⁶²	Ratze MAK...Derksen PWB	35437308	2022
12	Metastatic Breast Cancer Presenting as Progressive Ophthalmoplegia 30 Years After Initial Cancer Diagnosis. ⁶²	Karimaghaei S...Lee AG	34417769	2022
13	Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. ⁶²	Christgen M...Kreipe H	34889530	2022
14	Palpable multifocal and multicentric invasive lobular breast carcinoma in a young female. ⁶²	Qiu W...Hu TN	34876947	2022
15	Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ. ⁶²	Alexandres CA...Flanagan EP	34920159	2022
16	Case Report: Male Lobular Breast Cancer in Hereditary Cancer Syndromes. ⁶²	Carnevali I...Tibiletti MG	35686104	2022
17	Uterine metastasis of lobular breast carcinoma under tamoxifen therapy: A case report. ⁶²	Awazu Y...Sumi T	34777802	2021
18	Infiltrative pattern of metastatic invasive lobular breast carcinoma in the abdomen: a pictorial review. ⁶²	Wong YM...Pillay P	34894297	2021
19	Histiocytoid variant of invasive lobular breast carcinoma. A case report and literature review. ⁶²	Aldulaijan FA...Alwabari A	34868577	2021
20	Gastric metastasis before diagnosis of primary invasive lobular breast carcinoma: a rare case presentation from Pakistan. ⁶²	Ali M...Rasheed F	34569446	2021
21	Duodenal and Biliary Obstruction due to Extrinsic CompressionDuodenal and Biliary Obstruction due to Extrinsic Compression by Recurrent Lobular Breast Carcinoma: A Case Report. ⁶²	Bashir Hamidu R...Silver DP	34720837	2021
22	Occult Disseminated Metastatic Breast Carcinoma Presenting as Acquired Thrombotic Thrombocytopenic Purpura. ⁶²	Chong SL...Chang KM	35111014	2021
23	p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma. ⁶²	Acosta AM...Hirsch MS	33237989	2021
24	Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. ⁶²	Bergeron A...Arnould L	33753865	2021
25	Synchronous metastases of infiltrating lobular breast carcinoma to stomach and colon: ; rare but it does occur. ⁶²	Altundag K	34565039	2021
26	Lobular to Lobule: Metastatic Breast Carcinoma to Olfactory Neuroblastoma. ⁶²	Swimley KM...Thompson LDR	32661671	2021
27	An individualized food-based nutrition intervention reduces visceral and total body fat while preserving skeletal muscle mass in breast cancer patients under antineoplastic treatment. ⁶²	Limon-Miro AT...Astiazaran-Garcia H	33485708	2021
28	Breast carcinoma metastasising to the gastric wall and the peritoneum: what physicians need to know. ⁶²	Sohail A...Shah H	33980555	2021
29	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. ⁶²	Hosio M...Jukkola A	34001921	2021
30	Metastatic lobular carcinoma of the breast found incidentally on pathology following cholecystectomy for chronic cholecystitis: A case report. ⁶²	Salita A...Dinnan K	33636408	2021
31	Oncological cases and complications in Urology. ⁶²	Bernabei M...Barreira JV	33754614	2021
32	[From an enterovesical fistula to mammary carcinoma]. ⁶²	Comploj E...Trenti E	33757143	2021
33	Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population. ⁶²	Osmani AH...Suleman K	33544698	2021
34	Colorectal and gastric metastases from lobular breast cancer that resembled superficial neoplastic lesions. ⁶²	Kobayashi M...Ryozawa S	33159678	2021
35	Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing. ⁶²	Ito Y...Tsuta K	32770562	2021
36	Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. ⁶²	Alhenc-Gelas M...Bidard FC	33468209	2021
37	Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. ⁶²	Chen F...Lee AV	33148662	2021
38	The Impact of Radiotherapy on the Incidence of Secondary Malignancies: A Pan-Cancer Study in the US SEER Cancer Registries. ⁶²	Li W...Zhang Y	33435562	2021
39	An unusual presentation of cutaneous metastatic lobular breast carcinoma. ⁶²	Nahhas AF...Stephenson SR	33651872	2021
40	Unexpected diagnosis of metastatic breast carcinoma in an endomyocardial biopsy done for cardiac allograft rejection evaluation. ⁶²	Nair V...Veinot JP	32814149	2021
41	A Rare Metastatic Site of Invasive Lobular Breast Carcinoma: A Case Report. ⁶²	Husain S...Almarzooq R	34853710	2021
42	Enophthalmos as the Initial Systemic Finding of Undiagnosed Metastatic Breast Carcinoma. ⁶²	El-Khazen Dupuis J...Nguyen TQT	33536796	2021
43	Metastases to the Stomach: Clinicopathologic Features of Metastases Mimicking Gastric Primaries. ⁶²	Altay AY...Gulluoglu M	34514560	2021
44	Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/β-Catenin Complex and Associated Genetic Alterations. ⁶²	Del Valle Estopinal M...Williams MD	34804623	2021
45	Triple negative lobular breast carcinoma metastatic to an ovarian fibrothecoma. ⁶²	Strobel SL...Britton AJ	32508260	2020
46	Asymptomatic solitary metastasis to the stomach from breast cancer: A case report. ⁶²	Kaneko Y...Daimaru Y	33005409	2020
47	Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status. ⁶²	Li HN...Yang ZF	33058542	2020
48	Interaction Between Cyclosporine and Palbociclib in a Renal Transplant Patient: Case Report and Pharmacokinetic Perspective. ⁶²	Momper JD...Shah MM	31248333	2020
49	Colon metastases as first clinical manifestation of lobular breast carcinoma with no subsequent evidence of breast disease. ⁶²	Abu Zaanona MI...Rowland K	33257365	2020
50	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. ⁶²	Tille JC...Vincent-Salomon A	32404955	2020

Sources

Genes for Breast Lobular Carcinoma

Genes related to Breast Lobular Carcinoma (1 elite genes):

(show all 34)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CDH1	Cadherin 1	Protein Coding	408.02	Pathogenic ⁵ DISEASES inferred ¹⁴	8557030 17660459
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	9.06	DISEASES inferred ¹⁴
3	PGR	Progesterone Receptor	Protein Coding	8.95	DISEASES inferred ¹⁴
4	ESR1	Estrogen Receptor 1	Protein Coding	8.69	DISEASES inferred ¹⁴
5	PIP	Prolactin Induced Protein	Protein Coding	7.52	DISEASES inferred ¹⁴
6	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	7.23	DISEASES inferred ¹⁴
7	TP53	Tumor Protein P53	Protein Coding	7	DISEASES inferred ¹⁴
8	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	6.9	DISEASES inferred ¹⁴
9	KRT5	Keratin 5	Protein Coding	6.8	DISEASES inferred ¹⁴
10	GATA3	GATA Binding Protein 3	Protein Coding	6.74	DISEASES inferred ¹⁴
11	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.61	DISEASES inferred ¹⁴
12	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	6.56	DISEASES inferred ¹⁴
13	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.55	DISEASES inferred ¹⁴
14	CTNND1	Catenin Delta 1	Protein Coding	6.54	DISEASES inferred ¹⁴
15	KRT7	Keratin 7	Protein Coding	6.4	DISEASES inferred ¹⁴
16	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	6.2	DISEASES inferred ¹⁴
17	EGF	Epidermal Growth Factor	Protein Coding	6.15	DISEASES inferred ¹⁴
18	FOXA1	Forkhead Box A1	Protein Coding	6.15	DISEASES inferred ¹⁴
19	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.08	DISEASES inferred ¹⁴
20	AR	Androgen Receptor	Protein Coding	6.04	DISEASES inferred ¹⁴
21	CTNNB1	Catenin Beta 1	Protein Coding	6.02	DISEASES inferred ¹⁴
22	KRT14	Keratin 14	Protein Coding	5.86	DISEASES inferred ¹⁴
23	CDH17	Cadherin 17	Protein Coding	5.83	DISEASES inferred ¹⁴
24	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	5.82	DISEASES inferred ¹⁴
25	CCND1	Cyclin D1	Protein Coding	5.78	DISEASES inferred ¹⁴
26	KRT8	Keratin 8	Protein Coding	5.76	DISEASES inferred ¹⁴
27	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	5.75	DISEASES inferred ¹⁴
28	SNAI1	Snail Family Transcriptional Repressor 1	Protein Coding	5.74	DISEASES inferred ¹⁴
29	TBX3	T-Box Transcription Factor 3	Protein Coding	5.73	DISEASES inferred ¹⁴
30	MAP3K1	Mitogen-Activated Protein Kinase Kinase Kinase 1	Protein Coding	5.71	DISEASES inferred ¹⁴
31	CDH3	Cadherin 3	Protein Coding	5.7	DISEASES inferred ¹⁴
32	SNAI2	Snail Family Transcriptional Repressor 2	Protein Coding	5.68	DISEASES inferred ¹⁴
33	CDH2	Cadherin 2	Protein Coding	5.53	DISEASES inferred ¹⁴
34	PALB2	Partner And Localizer Of BRCA2	Protein Coding	5.5	DISEASES inferred ¹⁴

Sources

Variations for Breast Lobular Carcinoma

ClinVar genetic disease variations for Breast Lobular Carcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	CDH1	NM_004360.5(CDH1):c.781G>T (p.Glu261Ter)	SNV	Pathogenic	12234	rs121964873	GRCh37: 16:68844193-68844193 GRCh38: 16:68810290-68810290
2	CDH1	NM_004360.5(CDH1):c.521dup (p.Asn174fs)	DUP	Pathogenic	140803	rs587781290	GRCh37: 16:68842455-68842456 GRCh38: 16:68808552-68808553
3	CDH1	NM_004360.5(CDH1):c.1493A>C (p.Asp498Ala)	SNV	Not Provided	234528	rs876661065	GRCh37: 16:68849590-68849590 GRCh38: 16:68815687-68815687

Cosmic variations for Breast Lobular Carcinoma:

⁸ (show top 50) (show all 3466)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM88264551	ZRSR2	breast,NS,carcinoma,lobular carcinoma	c.772-1G>C	p.?	23:15818586-15818586	8
2	COSM87279654	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.4556C>G	p.S1519*	16:72798126-72798126	8
3	COSM149285883	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.4556C>G	p.S1519*	16:72798126-72798126	8
4	COSM149315898	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.7262C>G	p.S2421*	16:72795420-72795420	8
5	COSM102029000	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.1814C>G	p.S605*	16:72798126-72798126	8
6	COSM102040958	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.4520C>G	p.S1507*	16:72795420-72795420	8
7	COSM102023834	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.6478C>T	p.Q2160*	16:72793462-72793462	8
8	COSM149270832	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.9220C>T	p.Q3074*	16:72793462-72793462	8
9	COSM87290679	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.7262C>G	p.S2421*	16:72795420-72795420	8
10	COSM87274898	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.9220C>T	p.Q3074*	16:72793462-72793462	8
11	COSM136835751	YES1	breast,NS,carcinoma,lobular carcinoma	c.1105G>C	p.D369H	18:739782-739782	8
12	COSM152021957	YES1	breast,NS,carcinoma,lobular carcinoma	c.1090G>C	p.D364H	18:739782-739782	8
13	COSM89893843	YES1	breast,NS,carcinoma,lobular carcinoma	c.1090G>C	p.D364H	18:739782-739782	8
14	COSM133268543	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1078C>T	p.Q360*	11:102223703-102223703	8
15	COSM145023934	YAP1	breast,NS,carcinoma,lobular carcinoma	c.964C>T	p.Q322*	11:102223703-102223703	8
16	COSM128447630	YAP1	breast,NS,carcinoma,lobular carcinoma	c.952C>T	p.Q318*	11:102223703-102223703	8
17	COSM127994003	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1066C>T	p.Q356*	11:102223703-102223703	8
18	COSM126968980	YAP1	breast,NS,carcinoma,lobular carcinoma	c.580C>T	p.Q194*	11:102223703-102223703	8
19	COSM85232645	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1114C>T	p.Q372*	11:102223703-102223703	8
20	COSM143037036	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1126C>T	p.Q376*	11:102223703-102223703	8
21	COSM90943480	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1012C>T	p.Q338*	11:102223703-102223703	8
22	COSM101979646	XPO1	breast,NS,carcinoma,lobular carcinoma	c.1160C>G	p.S387C	2:61493979-61493979	8
23	COSM104239359	XPO1	breast,NS,carcinoma,lobular carcinoma	c.1160C>G	p.S387C	2:61493979-61493979	8
24	COSM104241154	XPO1	breast,NS,carcinoma,lobular carcinoma	c.2260G>T	p.E754*	2:61488218-61488218	8
25	COSM104886058	XPO1	breast,NS,carcinoma,lobular carcinoma	c.1160C>G	p.S387C	2:61493979-61493979	8
26	COSM101981526	XPO1	breast,NS,carcinoma,lobular carcinoma	c.2260G>T	p.E754*	2:61488218-61488218	8
27	COSM104888500	XPO1	breast,NS,carcinoma,lobular carcinoma	c.2260G>T	p.E754*	2:61488218-61488218	8
28	COSM108081568	XIAP	breast,NS,carcinoma,lobular carcinoma	c.1240C>G	p.L414V	23:123900633-123900633	8
29	COSM92178574	XIAP	breast,NS,carcinoma,lobular carcinoma	c.1240C>G	p.L414V	23:123900633-123900633	8
30	COSM94288275	XIAP	breast,NS,carcinoma,lobular carcinoma	c.1240C>G	p.L414V	23:123900633-123900633	8
31	COSM90876009	WNK1	breast,NS,carcinoma,lobular carcinoma	c.6569C>G	p.S2190C	12:900596-900596	8
32	COSM130224650	WNK1	breast,NS,carcinoma,lobular carcinoma	c.7349C>G	p.S2450C	12:900596-900596	8
33	COSM128151609	WNK1	breast,NS,carcinoma,lobular carcinoma	c.7808C>G	p.S2603C	12:900596-900596	8
34	COSM132334333	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	8
35	COSM132334343	WNK1	breast,NS,carcinoma,lobular carcinoma	c.5825C>G	p.S1942C	12:900596-900596	8
36	COSM90876002	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	8
37	COSM130224638	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	8
38	COSM92011980	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	8
39	COSM128151601	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	8
40	COSM92011987	WNK1	breast,NS,carcinoma,lobular carcinoma	c.7325C>G	p.S2442C	12:900596-900596	8
41	COSM88292485	VHL	breast,NS,carcinoma,lobular carcinoma	c.241C>T	p.P81S	3:10142088-10142088	8
42	COSM90665450	VHL	breast,NS,carcinoma,lobular carcinoma	c.439C>G	p.L147V	3:10149885-10149885	8
43	COSM90653017	VHL	breast,NS,carcinoma,lobular carcinoma	c.241C>T	p.P81S	3:10142088-10142088	8
44	COSM88303015	VHL	breast,NS,carcinoma,lobular carcinoma	c.562C>G	p.L188V	3:10149885-10149885	8
45	COSM133858401	USP28	breast,NS,carcinoma,lobular carcinoma	c.1675G>A	p.D559N	11:113809177-113809177	8
46	COSM83992324	USP28	breast,NS,carcinoma,lobular carcinoma	c.2050G>A	p.D684N	11:113809177-113809177	8
47	COSM132241970	USP28	breast,NS,carcinoma,lobular carcinoma	c.1174G>A	p.D392N	11:113809177-113809177	8
48	COSM140659623	TTN	breast,NS,carcinoma,lobular carcinoma	c.97193-1G>C	p.?	2:178542564-178542564	8
49	COSM96773374	TTN	breast,NS,carcinoma,lobular carcinoma	c.10945G>A	p.E3649K	2:178741574-178741574	8
50	COSM139462905	TTN	breast,NS,carcinoma,lobular carcinoma	c.40301G>A	p.R13434K	2:178621600-178621600	8

Sources

Expression for Breast Lobular Carcinoma

Search GEO for disease gene expression data for Breast Lobular Carcinoma.

Sources

Pathways for Breast Lobular Carcinoma

Pathways related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.83	TP53 PTEN PIP MUC1 ESR1 ERBB2
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.78	BRCA1 BRCA2 CDH1 CTNND1 CYP19A1 EGF
3	Signal Transduction ⁶⁶	13.74	AR CDH1 CTNND1 EGF EGFR ERBB2
4	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.5	BRCA1 BRCA2 EGF EGFR ERBB2 PIK3CA
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.43	TP53 PTEN PIP ERBB2 EGFR EGF
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.33	CDH1 CTNND1 EGF EGFR ERBB2 PIP
7	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.09	TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
8	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	13.01	PIK3CA PGR GATA3 FOXA1 ESR1 EGFR
9	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.97	TP53 PTEN PIK3CA FOXA1 EGFR EGF
10	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.87	CTNND1 EGF EGFR ERBB2 ESR1 PGR
11	Deubiquitination ⁶⁶ Show member pathways Ub-specific processing proteases ⁶⁶	12.85	TP53 PTEN GATA3 ESR1 BRCA1 AR
12	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.72	EGF EGFR ERBB2 ESR1 PIK3CA PTEN
13	Malignant pleural mesothelioma ⁷⁴	12.71	TP53 PTEN PIK3CA EGFR EGF CDH1
14	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.59	TP53 PTEN PIK3CA ERBB2 EGFR EGF
15	Cytoskeletal Signaling ³	12.57	MUC1 KRT7 KRT5 CTNND1 CDH1
16	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.5	TP53 PTEN PIK3CA ESR1 ERBB2 CDH1
17	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.46	TP53 PIK3CA ERBB2 EGFR
18	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.43	PIK3CA ESR1 EGFR EGF
19	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.41	CDH1 EGF EGFR ERBB2 PIK3CA
20	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.36	PIK3CA ESR1 ERBB2 EGFR EGF
21	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.35	TP53 PIK3CA MUC1 ERBB2 EGFR EGF
22	Focal adhesion ⁷⁴	12.32	PTEN PIK3CA ERBB2 EGFR EGF
23	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.3	PTEN PIK3CA EGFR EGF
24	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.29	TP53 PTEN PIK3CA GATA3
25	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.27	PIK3CA ERBB2 EGFR EGF
26	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.25	TP53 PTEN PIK3CA ERBB2 EGFR
27	Colorectal Cancer Metastasis ⁶⁴	12.22	TP53 EGFR EGF CDH1
28	mTOR Signaling ⁶⁵	12.13	TP53 PTEN ERBB2 EGFR
29	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.1	PTEN PIK3CA ERBB2 EGFR EGF AR
30	Direct p53 effectors ⁶¹	12.09	TP53 PTEN FOXA1 EGFR
31	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.09	TP53 PTEN PIK3CA PGR ESR1 ERBB2
32	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.07	EGF EGFR ERBB2 PIK3CA
33	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.06	TP53 PIK3CA ERBB2 EGFR
34	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.03	PIK3CA PGR ESR1 ERBB2 EGFR EGF
35	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	12.01	EGF EGFR ERBB2 PIK3CA PTEN
36	DNA damage response (only ATM dependent) ⁷⁴	11.96	TP53 PTEN PIK3CA ERBB2
37	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.87	ESR1 ERBB2 EGFR
38	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.84	BRCA1 BRCA2 TP53
39	DNA IR-damage and cellular response via ATR ⁷⁴	11.82	TP53 BRCA2 BRCA1
40	Glucocorticoid receptor regulatory network ⁶¹	11.8	TP53 KRT5 GATA3
41	Head and neck squamous cell carcinoma ⁷⁴	11.79	TP53 PTEN PIK3CA ERBB2 EGFR
42	Regulation of nuclear SMAD2/3 signaling ⁶¹	11.78	GATA3 ESR1 AR
43	16p11.2 proximal deletion syndrome ⁷⁴	11.78	TP53 PTEN ESR1
44	AP-1 transcription factor network ⁶¹	11.74	TP53 PTEN ESR1
45	Regulation of Telomerase ⁶¹	11.73	ESR1 EGFR EGF
46	Validated nuclear estrogen receptor alpha network ⁶¹	11.71	PGR ESR1 BRCA1
47	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.67	TP53 PTEN PIK3CA ERBB2 BRCA1
48	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.66	TP53 PTEN PIK3CA
49	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.66	PIK3CA ERBB2 EGFR EGF
50	SHP2 signaling ⁶¹	11.62	PIK3CA EGFR EGF

Sources

GO Terms for Breast Lobular Carcinoma

Cellular components related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nuclear ubiquitin ligase complex	GO:0000152	8.92	BRCA2 BRCA1

Biological processes related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of DNA-templated transcription	GO:0045893	10.32	TP53 GATA3 ESR1 EGFR EGF CDH1
2	positive regulation of protein kinase B signaling	GO:0051897	10.18	PIK3CA GATA3 EGFR EGF
3	cellular response to ionizing radiation	GO:0071479	10.06	TP53 BRCA2 BRCA1
4	negative regulation of epithelial to mesenchymal transition	GO:0010719	10.04	PTEN GATA3 FOXA1
5	phosphatidylinositol 3-kinase signaling	GO:0014065	10.03	PTEN PIK3CA GATA3 ERBB2
6	positive regulation of phosphorylation	GO:0042327	10.01	EGFR EGF AR
7	response to gamma radiation	GO:0010332	9.99	TP53 GATA3 BRCA2
8	uterus development	GO:0060065	9.97	GATA3 ESR1 CYP19A1
9	mammary gland alveolus development	GO:0060749	9.95	ESR1 EGF AR
10	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.93	BRCA2 MUC1 TP53
11	positive regulation of transcription from RNA polymerase II promoter in response to stress	GO:0036003	9.91	TP53 MUC1
12	cellular response to indole-3-methanol	GO:0071681	9.9	CDH1 BRCA1
13	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.89	TP53 ESR1
14	intracellular steroid hormone receptor signaling pathway	GO:0030518	9.88	PGR ESR1 AR
15	cell population proliferation	GO:0008283	9.87	BRCA2 EGF EGFR GATA3 PTEN TP53
16	negative regulation of mammary gland epithelial cell proliferation	GO:0033600	9.86	BRCA2 GATA3
17	morphogenesis of an epithelial fold	GO:0060571	9.85	AR EGFR
18	tertiary branching involved in mammary gland duct morphogenesis	GO:0060748	9.83	PGR AR
19	positive regulation of gene expression	GO:0010628	9.8	TP53 PIP PGR GATA3 ERBB2 EGF
20	chordate embryonic development	GO:0043009	9.78	BRCA2 BRCA1
21	prostate gland growth	GO:0060736	9.73	PTEN CYP19A1 AR
22	ERBB2-EGFR signaling pathway	GO:0038134	9.63	ERBB2 EGFR EGF
23	positive regulation of miRNA transcription	GO:1902895	9.17	TP53 GATA3 FOXA1 EGFR AR

Molecular functions related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA-binding transcription activator activity, RNA polymerase II-specific	GO:0001228	10.21	TP53 PGR GATA3 FOXA1 ESR1 AR
2	identical protein binding	GO:0042802	10.2	BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
3	transcription cis-regulatory region binding	GO:0000976	10.1	TP53 GATA3 FOXA1 BRCA1 AR
4	beta-catenin binding	GO:0008013	9.92	ESR1 CTNND1 CDH1 AR
5	ATPase binding	GO:0051117	9.86	PGR ESR1 EGFR AR
6	steroid binding	GO:0005496	9.85	AR ESR1 PGR
7	enzyme binding	GO:0019899	9.8	TP53 PTEN PGR ESR1 EGFR BRCA1
8	transcription coactivator binding	GO:0001223	9.23	PGR GATA3 ESR1 AR